...
首页> 外文期刊>Transplant infectious disease: an official journal of the Transplantation Society >Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient.
【24h】

Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient.

机译:在异基因干细胞移植接受者接受伏立康唑预防的同时突破突破多孢子藻的感染。

获取原文
获取原文并翻译 | 示例

摘要

Breakthrough invasive fungal infections among patients with hematologic malignancies receiving voriconazole are being reported with increasing frequency, with zygomycete infections predominating. We report a case of disseminated Scedosporium prolificans infection in a patient receiving voriconazole prophylaxis. Despite poor in vitro activity of voriconazole for this organism, synergy studies using the checkerboard method demonstrated synergy with the combination of voriconazole and terbinafine. This regimen, in conjunction with central venous line removal and intravitreal voriconazole, contributed to the recovery of the patient. S. prolificans is a life-threatening mold that should be considered in patients with breakthrough invasive fungal infections while on voriconazole prophylaxis.
机译:据报道,接受伏立康唑的血液系统恶性肿瘤患者中突破性侵袭性真菌感染的发生频率不断上升,合子菌感染占主导地位。我们报告了一例接受伏立康唑预防的患者中传播了多孢子虫。尽管伏立康唑对该生物体的体外活性较差,但使用棋盘法进行的协同研究表明,伏立康唑与特比萘芬的组合具有协同作用。该方案与中心静脉线清除和玻璃体内伏立康唑联合使用,有助于患者康复。 S. prolificans是一种威胁生命的霉菌,在预防伏立康唑的同时具有突破性侵袭性真菌感染的患者应考虑使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号